Clinical Trial

An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH

Study acronym: PROCHASE-DoE
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, dose-escalation study on the safety, tolerability and preliminary efficacy for preventing stroke-associated pneumonia of propranolol in patients with intracerebral hemorrhage. Propranolol is administered via intravenous pump continuously for 7 days.
Trial Details
NCT Number NCT07528235
Lead Sponsor Tang-Du Hospital
Conditions Intracerebral Hemorrhage, Stroke-Associated Pneumonia (SAP)
Enrollment 30 participants
Start Date 2026-05-01
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-14